Estrella Immunopharma (ESLA) Cash & Equivalents (2021 - 2026)

Estrella Immunopharma (ESLA) has reported Cash & Equivalents for 6 consecutive years, with $1.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 357.3% year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $1.9 million (up 357.3% YoY), while the FY2025 annual figure was $1.4 million, up 50.97% from the prior year.
• Cash & Equivalents improved to $1.9 million in Q1 2026 per ESLA's latest filing, from $1.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $22.1 million in Q3 2023 and bottomed at $29390.0 in Q1 2023.
• Historically, Cash & Equivalents has averaged $3.1 million across 5 years, with a median of $1.4 million in 2025.
• Annual changes were most pronounced in 2023 — Cash & Equivalents surged 29916.81% — and 2024, when it slumped 91.87%.
• Estrella Immunopharma's Cash & Equivalents stood at $40802.0 in 2022, then soared by 22070.52% to $9.0 million in 2023, then tumbled by 89.86% to $916916.0 in 2024, then soared by 50.97% to $1.4 million in 2025, then soared by 39.23% to $1.9 million in 2026.
• Business Quant data shows ESLA's Cash & Equivalents at $1.9 million in Q1 2026, $1.4 million in Q4 2025, and $1.6 million in Q3 2025.